We found that there was no serious limitation in consistency and directness because the evidence came from research that directly compared SGLT2 inhibitors versus placebo or active hypoglycemia drugs in type 2 diabetes patients, and the tests showed low heterogeneity. Here, SLC5A2 is linked to Hypoglycemia.